AR053304A1 - Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. - Google Patents
Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion.Info
- Publication number
- AR053304A1 AR053304A1 ARP050102719A ARP050102719A AR053304A1 AR 053304 A1 AR053304 A1 AR 053304A1 AR P050102719 A ARP050102719 A AR P050102719A AR P050102719 A ARP050102719 A AR P050102719A AR 053304 A1 AR053304 A1 AR 053304A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical form
- polymer
- wax
- phenol
- synthetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Una forma farmacéutica oral, protegida frente al abuso, con liberacion controlada de (1R,2R)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol para una administracion unica diaria, caracterizada porque comprende el principio activo (A) y/o al menos uno varios de sus compuestos farmacéuticamente aceptables, al menos un polímero (C) sintético y/o natural, adyuvantes de liberacion sostenida, opcionalmente otros adyuvantes (B) fisiologicamente compatibles y opcionalmente una cera (D), de modo que el componente (C) o (D) presenta, cada uno, una resistencia a la rotura de al menos 500 N, preferiblemente de al menos 750 N. Reivindicacion 8: Forma farmacéutica segun una de las reivindicaciones 1 a 7, caracterizada porque el polímero (C) es a menos un polímero seleccionado del grupo que comprende poli(oxidos de etileno), polietilenos, polipropilenos, poli(cloruros de vinilo), policarbonatos, poliestirenos, poli(met)acrilatos, sus copolímeros y mezclas de al menos dos representantes de las clases poliméricas o polímeros mencionados. Reivindicacion 16. Forma farmacéutica segun una de las reivindicaciones 1 a 15, caracterizada porque como cera (D) está presente al menos una cera natural, semisintética y/o sintética con un punto de ablandamiento de al menos en 60°C. Reivindicacion 23: Forma farmacéutica segun una de las reivindicaciones 1 a 22, caracterizada porque presenta como adyuvante (B) al menos uno de los siguientes componentes (a9-(f) que impiden el abuso: a) al menos una sustancia que irrita la cavidad nasal y/o faríngea; b) al menos un agente que aumenta la viscosidad que, con ayuda de una cantidad mínima necesaria de un líquido acuoso, preferiblemente como un extracto acuoso obtenido a partir de la forma farmacéutica, forma un gel que preferiblemente al introducirlo en otra cantidad de un líquido acuoso puede seguir distinguiéndose visualmente; c) al menos un antagonista para el principio activo con potencial de crear dependencia; d) al menos un emético; e) al menos un colorante como agente de rechazo, f) al menos una sustancia amarga.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102004032103A DE102004032103A1 (de) | 2004-07-01 | 2004-07-01 | Gegen Missbrauch gesicherte, orale Darreichungsform |
| US10/890,707 US20060039864A1 (en) | 2004-07-01 | 2004-07-14 | Abuse-proofed oral dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR053304A1 true AR053304A1 (es) | 2007-05-02 |
Family
ID=34972022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102719A AR053304A1 (es) | 2004-07-01 | 2005-06-29 | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1786403B1 (es) |
| JP (1) | JP5700904B2 (es) |
| KR (1) | KR101204657B1 (es) |
| AR (1) | AR053304A1 (es) |
| AU (1) | AU2005259478B2 (es) |
| BR (1) | BRPI0513300B1 (es) |
| CA (1) | CA2572352A1 (es) |
| NO (1) | NO337952B1 (es) |
| PL (1) | PL1786403T3 (es) |
| WO (1) | WO2006002886A1 (es) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US8114384B2 (en) | 2004-07-01 | 2012-02-14 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
| US8192722B2 (en) | 2003-08-06 | 2012-06-05 | Grunenthal Gmbh | Abuse-proof dosage form |
| US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| US8722086B2 (en) | 2007-03-07 | 2014-05-13 | Gruenenthal Gmbh | Dosage form with impeded abuse |
| US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2957281A1 (en) | 2001-09-21 | 2015-12-23 | Egalet Ltd. | Polymer release system |
| EP1429744A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Morphine polymer release system |
| JP4732696B2 (ja) | 2002-04-09 | 2011-07-27 | フラメル・テクノロジー | 活性成分の改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤 |
| ES2360102T3 (es) | 2003-03-26 | 2011-05-31 | Egalet A/S | Sistema para la liberación controlada de morfina. |
| FR2901478B1 (fr) * | 2006-05-24 | 2015-06-05 | Flamel Tech Sa | Forme pharmaceutique orale multimicroparticulaire a liberation prolongee |
| US9023400B2 (en) | 2006-05-24 | 2015-05-05 | Flamel Technologies | Prolonged-release multimicroparticulate oral pharmaceutical form |
| SA07280459B1 (ar) | 2006-08-25 | 2011-07-20 | بيورديو فارما إل. بي. | أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| WO2010089132A1 (en) | 2009-02-06 | 2010-08-12 | Egalet A/S | Immediate release composition resistant to abuse by intake of alcohol |
| CA2766179A1 (en) | 2009-06-24 | 2010-12-29 | Egalet Ltd. | Controlled release formulations |
| US8397733B2 (en) * | 2010-01-15 | 2013-03-19 | Celanese Acetate Llc | Degradable cigarette filter: pill with multilayered coating |
| CN102821757B (zh) | 2010-02-03 | 2016-01-20 | 格吕伦塔尔有限公司 | 通过挤出机制备粉末状药物组合物 |
| WO2011124953A2 (en) * | 2010-04-07 | 2011-10-13 | Lupin Limited | Controlled release pharmaceutical compositions of tapentadol |
| ES3035088T3 (en) | 2010-07-23 | 2025-08-28 | Gruenenthal Gmbh | Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol |
| AR082861A1 (es) | 2010-09-02 | 2013-01-16 | Gruenenthal Gmbh | Forma de dosificacion resistente a alteracion que comprende un polimero anionico |
| JP6046057B2 (ja) | 2011-03-04 | 2016-12-14 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 経口投与用タペンタドールの水性医薬製剤 |
| KR101903351B1 (ko) | 2011-03-04 | 2018-10-04 | 그뤼넨탈 게엠베하 | 타펜타돌의 비경구 투여 |
| JP6027549B2 (ja) | 2011-03-04 | 2016-11-16 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | タペンタドールを含む半固形の水性医薬組成物 |
| BR112014008120A2 (pt) | 2011-10-06 | 2017-04-11 | Gruenenthal Gmbh | forma inviolável de dosagem farmacêutica oral compreendendo agonista de opioide e antagonista de opioide |
| CN104066426A (zh) | 2011-11-17 | 2014-09-24 | 格吕伦塔尔有限公司 | 包含药理学活性成分、阿片样物质拮抗剂和/或厌恶剂、聚环氧烷和阴离子聚合物的抗损坏口服药物剂型 |
| EP2819657A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant pharmaceutical dosage form comprising nonionic surfactant |
| PL2846835T3 (pl) | 2012-05-11 | 2018-02-28 | Grünenthal GmbH | Kształtowana termicznie, odporna na manipulacje farmaceutyczna postać dawkowania zawierająca cynk |
| AU2013285988A1 (en) | 2012-07-06 | 2015-02-12 | Egalet Ltd. | Abuse deterrent pharmaceutical compositions for controlled release |
| WO2014106865A1 (en) * | 2013-01-07 | 2014-07-10 | Alkem Laboratories Ltd. | Abuse-proofed, extended release pharmaceutical composition comprising tapentadol or a pharmaceutically acceptable salt thereof and processes for preparing thereof |
| EP2808319A1 (en) | 2013-05-31 | 2014-12-03 | Arevipharma GmbH | 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex |
| WO2015071248A1 (en) | 2013-11-15 | 2015-05-21 | Synthon B.V. | Abuse-proofed extended release pharmaceutical composition comprising tapentadol |
| JP2016540798A (ja) | 2013-12-16 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 共押出により製造される、二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ ｒｅｓｉｓｔａｎｔ）剤形 |
| JP2018503693A (ja) | 2015-02-03 | 2018-02-08 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | ポリエチレングリコールグラフトコポリマーを含む改変防止剤形 |
| MX2017012312A (es) | 2015-03-27 | 2018-01-18 | Gruenenthal Gmbh | Formulacion estable para administracion parenteral de tapentadol. |
| JP2018513872A (ja) | 2015-04-24 | 2018-05-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 異なる粒子から２種の薬物の急速放出をもたらすタンパレジスタントな固定用量組合せ |
| WO2016170094A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles |
| EP3285744A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant fixed dose combination providing fast release of two drugs from particles and a matrix |
| PL3377049T3 (pl) | 2015-11-17 | 2021-06-28 | Msn Laboratories Private Limited | Krystaliczne formy soli tapentadolu i sposób ich wytwarzania |
| KR20170003380U (ko) | 2016-03-21 | 2017-09-29 | 정화정 | 공기주입식 간판의 받침장치 |
| US20170296476A1 (en) | 2016-04-15 | 2017-10-19 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
| WO2018007507A1 (en) | 2016-07-06 | 2018-01-11 | Grünenthal GmbH | Reinforced pharmaceutical dosage form |
| AU2017307235A1 (en) | 2016-08-01 | 2019-01-31 | Grünenthal GmbH | Tamper resistant dosage form comprising an anionic polysaccharide |
| TW201811313A (zh) | 2016-08-12 | 2018-04-01 | 德商歌林達有限公司 | 麻黃鹼和其衍生物的防損壞製劑 |
| WO2018055070A1 (en) | 2016-09-23 | 2018-03-29 | Grünenthal GmbH | Stable formulation for parenteral administration of tapentadol |
| WO2018153947A1 (en) | 2017-02-23 | 2018-08-30 | Grünenthal GmbH | Tapentadol as local anesthetic |
| US20190110992A1 (en) | 2017-10-13 | 2019-04-18 | Grünenthal GmbH | Modified release abuse deterrent dosage forms |
| TW202002957A (zh) | 2018-02-09 | 2020-01-16 | 德商歌林達有限公司 | 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物 |
| EP3698776A1 (en) | 2019-02-19 | 2020-08-26 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2020100442B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| EP3875080B1 (en) | 2020-03-02 | 2025-12-31 | Grünenthal GmbH | EXTENDED-RELEASE DOSAGE FORM OF PHOSPHORIC ACID SALT OF TAPENTADOL |
| RS65074B1 (sr) * | 2020-03-02 | 2024-02-29 | Gruenenthal Gmbh | Dozni oblik sa produženim oslobađanjem soli tapentadola sa fosfornom kiselinom |
| AU2020100441B4 (en) * | 2020-03-02 | 2020-06-18 | Grünenthal GmbH | Dosage form providing prolonged release of tapentadol phosphoric acid salt |
| DE202021003994U1 (de) | 2020-03-02 | 2022-04-12 | Grünenthal GmbH | Dosierungsform mit verlängerter Freisetzung von Tapentadol-Phosphorsäuresalz |
| WO2021219577A1 (en) | 2020-04-27 | 2021-11-04 | Grünenthal GmbH | Dosage form comprising hot-melt extruded pellets containing eva copolymer and gliding agent |
| WO2021219576A1 (en) | 2020-04-27 | 2021-11-04 | Grünenthal GmbH | Multiparticulate dosage form containing eva copolymer and additional excipient |
| DE202020104285U1 (de) | 2020-07-24 | 2020-12-18 | Grünenthal GmbH | Ethylcellulose-beschichtete Partikel enthaltend ein Salz aus Tapentadol und Phosphorsäure |
| WO2022101247A1 (de) | 2020-11-10 | 2022-05-19 | Grünenthal GmbH | Darreichungsformen mit verlängerter freisetzung eines salzes von tapentadol mit l-(+)-weinsäure |
| PT3995135T (pt) | 2020-11-10 | 2022-09-08 | Gruenenthal Gmbh | Forma de dosagem que proporciona libertação prolongada de um sal de tapentadol com ácido l-(+)-tartárico |
| DE202020005470U1 (de) | 2020-11-10 | 2022-01-25 | Grünenthal GmbH | Darreichungsformen mit verlängerter Freisetzung eines Salzes von Tapentadol mit L-(+)-Weinsäure |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5004601A (en) * | 1988-10-14 | 1991-04-02 | Zetachron, Inc. | Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith |
| AU2059297A (en) * | 1996-03-12 | 1997-10-01 | Alza Corporation | Composition and dosage form comprising opioid antagonist |
| US7332182B2 (en) * | 2001-08-06 | 2008-02-19 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant |
| US7144587B2 (en) * | 2001-08-06 | 2006-12-05 | Euro-Celtique S.A. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent |
| PE20030527A1 (es) * | 2001-10-24 | 2003-07-26 | Gruenenthal Chemie | Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen |
| DE10250083A1 (de) * | 2002-06-17 | 2003-12-24 | Gruenenthal Gmbh | Gegen Missbrauch gesicherte Darreichungsform |
| CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
| DE10250084A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10250088A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10250087A1 (de) * | 2002-10-25 | 2004-05-06 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
-
2005
- 2005-06-29 CA CA002572352A patent/CA2572352A1/en not_active Abandoned
- 2005-06-29 AR ARP050102719A patent/AR053304A1/es not_active Application Discontinuation
- 2005-06-29 WO PCT/EP2005/006990 patent/WO2006002886A1/de not_active Ceased
- 2005-06-29 EP EP05758495.5A patent/EP1786403B1/de not_active Expired - Lifetime
- 2005-06-29 AU AU2005259478A patent/AU2005259478B2/en not_active Ceased
- 2005-06-29 JP JP2007518529A patent/JP5700904B2/ja not_active Expired - Fee Related
- 2005-06-29 KR KR1020077000734A patent/KR101204657B1/ko not_active Expired - Fee Related
- 2005-06-29 BR BRPI0513300A patent/BRPI0513300B1/pt not_active IP Right Cessation
- 2005-06-29 PL PL05758495T patent/PL1786403T3/pl unknown
-
2007
- 2007-01-31 NO NO20070578A patent/NO337952B1/no not_active IP Right Cessation
Cited By (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9675610B2 (en) | 2002-06-17 | 2017-06-13 | Grünenthal GmbH | Abuse-proofed dosage form |
| US10369109B2 (en) | 2002-06-17 | 2019-08-06 | Grünenthal GmbH | Abuse-proofed dosage form |
| US8114383B2 (en) | 2003-08-06 | 2012-02-14 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US8192722B2 (en) | 2003-08-06 | 2012-06-05 | Grunenthal Gmbh | Abuse-proof dosage form |
| US8309060B2 (en) | 2003-08-06 | 2012-11-13 | Grunenthal Gmbh | Abuse-proofed dosage form |
| US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
| US10130591B2 (en) | 2003-08-06 | 2018-11-20 | Grünenthal GmbH | Abuse-proofed dosage form |
| US8420056B2 (en) | 2003-08-06 | 2013-04-16 | Grunenthal Gmbh | Abuse-proofed dosage form |
| US10058548B2 (en) | 2003-08-06 | 2018-08-28 | Grünenthal GmbH | Abuse-proofed dosage form |
| US9629807B2 (en) | 2003-08-06 | 2017-04-25 | Grünenthal GmbH | Abuse-proofed dosage form |
| US11224576B2 (en) | 2003-12-24 | 2022-01-18 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US11844865B2 (en) | 2004-07-01 | 2023-12-19 | Grünenthal GmbH | Abuse-proofed oral dosage form |
| US8114384B2 (en) | 2004-07-01 | 2012-02-14 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
| US8323889B2 (en) | 2004-07-01 | 2012-12-04 | Gruenenthal Gmbh | Process for the production of an abuse-proofed solid dosage form |
| US10729658B2 (en) | 2005-02-04 | 2020-08-04 | Grünenthal GmbH | Process for the production of an abuse-proofed dosage form |
| US10675278B2 (en) | 2005-02-04 | 2020-06-09 | Grünenthal GmbH | Crush resistant delayed-release dosage forms |
| US8722086B2 (en) | 2007-03-07 | 2014-05-13 | Gruenenthal Gmbh | Dosage form with impeded abuse |
| US8383152B2 (en) | 2008-01-25 | 2013-02-26 | Gruenenthal Gmbh | Pharmaceutical dosage form |
| US9750701B2 (en) | 2008-01-25 | 2017-09-05 | Grünenthal GmbH | Pharmaceutical dosage form |
| US9161917B2 (en) | 2008-05-09 | 2015-10-20 | Grünenthal GmbH | Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet |
| US9925146B2 (en) | 2009-07-22 | 2018-03-27 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10080721B2 (en) | 2009-07-22 | 2018-09-25 | Gruenenthal Gmbh | Hot-melt extruded pharmaceutical dosage form |
| US10493033B2 (en) | 2009-07-22 | 2019-12-03 | Grünenthal GmbH | Oxidation-stabilized tamper-resistant dosage form |
| US10300141B2 (en) | 2010-09-02 | 2019-05-28 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| US9636303B2 (en) | 2010-09-02 | 2017-05-02 | Gruenenthal Gmbh | Tamper resistant dosage form comprising an anionic polymer |
| US10864164B2 (en) | 2011-07-29 | 2020-12-15 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10695297B2 (en) | 2011-07-29 | 2020-06-30 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
| US10201502B2 (en) | 2011-07-29 | 2019-02-12 | Gruenenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
| US9655853B2 (en) | 2012-02-28 | 2017-05-23 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US10335373B2 (en) | 2012-04-18 | 2019-07-02 | Grunenthal Gmbh | Tamper resistant and dose-dumping resistant pharmaceutical dosage form |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10154966B2 (en) | 2013-05-29 | 2018-12-18 | Grünenthal GmbH | Tamper-resistant dosage form containing one or more particles |
| US9737490B2 (en) | 2013-05-29 | 2017-08-22 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| US10624862B2 (en) | 2013-07-12 | 2020-04-21 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| US10449547B2 (en) | 2013-11-26 | 2019-10-22 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| US9913814B2 (en) | 2014-05-12 | 2018-03-13 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US9855263B2 (en) | 2015-04-24 | 2018-01-02 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008504328A (ja) | 2008-02-14 |
| KR101204657B1 (ko) | 2012-11-27 |
| KR20070039041A (ko) | 2007-04-11 |
| NO20070578L (no) | 2007-01-31 |
| PL1786403T3 (pl) | 2013-10-31 |
| CA2572352A1 (en) | 2006-01-12 |
| BRPI0513300A (pt) | 2008-05-06 |
| AU2005259478A1 (en) | 2006-01-12 |
| JP5700904B2 (ja) | 2015-04-15 |
| BRPI0513300B1 (pt) | 2018-11-06 |
| EP1786403B1 (de) | 2013-07-24 |
| WO2006002886A1 (de) | 2006-01-12 |
| EP1786403A1 (de) | 2007-05-23 |
| NO337952B1 (no) | 2016-07-18 |
| AU2005259478B2 (en) | 2010-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR053304A1 (es) | Formas farmaceuticas orales protegidas frente al abuso con liberacion controlada de (1r,2r)-3-(3 dimetilamino-1-etil-2metil-propil)fenol y procedimiento para su produccion. | |
| AR049562A1 (es) | Formas farmaceuticas orales, con liberacion controlada de opioides, protegidas frente al abuso y procedimiento para su preparacion | |
| PE20061087A1 (es) | Formas farmaceuticas resistente a la rotura con liberacion sostenida | |
| ES2338993T3 (es) | Jeringuilla para disoluciones viscoelasticas. | |
| HRP20130715T1 (hr) | Oralni oblik doziranja osiguran protiv zlouporabe koji sadrži (1r, 2r)-3-(3-dimetilamino-1-etil-2-metil-propil)-fenol | |
| PE20060523A1 (es) | Formas farmaceuticas orales de opioides con liberacion controlada | |
| AR073460A1 (es) | Dispositivo oftalmico con capacidad de administracion de agente terapeutico y metodo de formacion del mismo | |
| WO2004112748A3 (en) | Rate controlled release of a pharmaceutical agent in a biodegradable device | |
| DE60231862D1 (de) | Erodierbare polymere zur injektion | |
| BRPI0707044B8 (pt) | comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais | |
| BRPI0413381A (pt) | composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas | |
| AR045352A1 (es) | Forma de dosificacion a prueba de abuso | |
| AR063619A1 (es) | Dispositivos y metodos para la administraicion de un farmaco oftalmico | |
| WO2005099667A3 (en) | Drug delivery compositions | |
| AR034324A1 (es) | Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas | |
| WO2016042163A3 (en) | Ophthalmic drug compositions | |
| BR0212475A (pt) | Composições farmacêuticas | |
| WO2010068281A3 (en) | Contact lens drug delivery device | |
| AR048033A1 (es) | Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion | |
| PE20061204A1 (es) | Procedimiento para producir una forma farmaceutica protegida frente al uso fraudulento | |
| BRPI0506983A (pt) | composições para terapia localizada dos olhos, compreendendo preferencialmente acetonida de triancinolona e ácido hialurÈnico | |
| BRPI0607483A2 (pt) | microimplantes para administração ocular | |
| BRPI0713715A2 (pt) | plugues punctais para a entrega de agentes ativos | |
| CY1109606T1 (el) | Βιοδιασπωμενο υμενιο για την απελευθερωση φαρμακου στον οφθαλμο | |
| KR20120013346A (ko) | 누점 마개 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |